Header Graphic
Drug Discovery, Drug Delivery, and Biochemical Assays
ProFoldin’s products and services are employed by universities, research institutes, biotech
companies, pharmaceutical R&D and research hospitals worldwide in life sciences and drug discovery.
COVID-19 Drug target assays

 

 

SARS-CoV-2 RNA Polymerase (RdRp) Assay for Drug Discovery

 

The COVID-19 pandemic is caused by infection of SARS-CoV-2 or severe acute respiratory syndrome coronavirus 2, a positive-sense single-stranded RNA virus. The RNA dependent RNA polymerase (RdRp) is a key drug target for this deadly virus. The SARS-CoV-2 RdRP assay is based on detection of the RNA molecules synthesized by the RNA polymerase in the presence of an RNA template and NTPs. The assay can be performed in a 384-well or 96-well plate format for tests of the enzyme activities of the virus RNA polymerase (SARS-CoV-2 RdRp) and high throughput screening of inhibitors.   

The SARS-CoV-2 RNA polymerase assay kit-100 (Catalog No.S2RPA100K) includes 300 µl of 10 x Buffer, 50 µl of 50 x RNA template, 60 µl of 50 x  mM NTPs (ATP, UTP, GTP, CTP) and 700 µl of 10 x fluorescence dye. It is for 100 assays of SARS-CoV-2 RNA polymerase in a 384-well plate format or 50 assays in a 96-well plate format. The assay kit includes all reagents except the enzyme. 

The SARS-CoV-2 RNA polymerase assay kit plus-20 (Catalog No.S2RPA020KE) includes 75 µl of 10 x Buffer,  10 µl of 50 x RNA template, 12 µl of 50 x NTPs (ATP, UTP, GTP, CTP), 150 µl of 10 x fluorescence dye and  10 µl of 50 x SARS-CoV-2 RdRp.  It is for 20 assays of SARS-CoV-2 RNA polymerase in a 384-well plate format or 10 assays in a 96-well plate format.  

The SARS-CoV-2 RNA polymerase assay kit plus-100 (Catalog No.S2RPA100KE) includes 300 µl of 10 x Buffer, 50 µl of 50 x RNA template, 60 µl of 50 x  mM NTPs (ATP, UTP, GTP, CTP), 700 µl of 10 x fluorescence dye and  50 µl of 50 x SARS-CoV-2 RdRp.  It is for 100 assays of SARS-CoV-2 RNA polymerase in a 384-well plate format or 50 assays in a 96-well plate format.